Across the recent three months, 7 analysts have shared their insights on Avidity Biosciences RNA, expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 5 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 3 | 0 | 0 | 0 |
| 2M Ago | 2 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $68.86, a high estimate of $96.00, and a low estimate of $53.00. Observing a 4.33% increase, the current average has risen from the previous average price target of $66.00.
Exploring Analyst Ratings: An In-Depth Overview
In examining recent analyst actions, we gain insights into how financial experts perceive Avidity Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Eric Schmidt | Cantor Fitzgerald | Maintains | Overweight | $96.00 | $96.00 |
| Eric Schmidt | Cantor Fitzgerald | Maintains | Overweight | $96.00 | $96.00 |
| Gena Wang | Barclays | Announces | Overweight | $63.00 | - |
| Josh Schimmer | Evercore ISI Group | Lowers | Outperform | $53.00 | $54.00 |
| Joseph Stringer | Needham | Maintains | Buy | $60.00 | $60.00 |
| Josh Schimmer | Evercore ISI Group | Raises | Outperform | $54.00 | $45.00 |
| Keay Nakae | Chardan Capital | Raises | Buy | $60.00 | $45.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Avidity Biosciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Avidity Biosciences compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Avidity Biosciences's stock. This comparison reveals trends in analysts' expectations over time.
To gain a panoramic view of Avidity Biosciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Avidity Biosciences analyst ratings.
Discovering Avidity Biosciences: A Closer Look
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
Financial Insights: Avidity Biosciences
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Avidity Biosciences faced challenges, resulting in a decline of approximately -11.7% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Avidity Biosciences's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -3461.76%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -6.9%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Avidity Biosciences's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -6.16%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Avidity Biosciences's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
Understanding the Relevance of Analyst Ratings
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
